Investors & Media

press releases

Date Title Teaser
03/22/19
Summary Togglebluebird bio Opens State-of-the-Art Gene and Cell Therapy Manufacturing Facility in Durham, North Carolina Gov. Cooper to cut ribbon on facility that will strengthen bluebird bio's capabilities to manufacture products for clinical development and commercial supply CAMBRIDGE, Mass. & DURHAM, N.C. --(BUSINESS WIRE)--Mar. 22, 2019-- bluebird bio, Inc. (Nasdaq: BLUE) today announced the official opening of
03/08/19
Summary Togglebluebird bio to Present at Investor Conferences in March CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 8, 2019-- bluebird bio, Inc . (Nasdaq: BLUE) today announced that members of the management team will present at the following upcoming investor conferences: Cowen and Company 39 th Annual Health Care Conference , Tuesday, March 12 , at 8:40 am ET at the
02/21/19
Summary Togglebluebird bio Reports Fourth Quarter and Full Year 2018 Financial Results and Highlights Operational Progress - Strong 2018 marked by the company’s first European Marketing Authorization Application for LentiGlobin in transfusion-dependent β-thalassemia (TDT) – - Data across LentiGlobin studies in TDT and sickle cell disease (SCD) and bb21217 in multiple myeloma presented at American Society of Hematology
02/11/19
Summary Togglebluebird bio Appoints Chip Baird as Chief Financial Officer CFO with proven track record will help lead transition to commercial company Jeff Walsh to assume role of chief strategy officer Jason Cole to assume role of chief operating and legal officer CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 11, 2019-- bluebird bio, Inc .
01/07/19
Summary Togglebluebird bio and Inhibrx Announce Collaboration to Research, Develop and Commercialize CAR T Cell Immunotherapies CAMBRIDGE, Mass. & SAN DIEGO --(BUSINESS WIRE)--Jan. 7, 2019-- bluebird bio, Inc . (Nasdaq: BLUE) and Inhibrx, Inc. (Inhibrx) today announced that they have entered into an exclusive license agreement to research, develop and commercialize chimeric antigen receptor (CAR) T cell therapies using
01/03/19
Summary Togglebluebird bio to Present at the 37th Annual J.P. Morgan Healthcare Conference CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jan. 3, 2019-- bluebird bio, Inc. (Nasdaq: BLUE) today announced that members of the management team will present at the 37 th Annual J.P. Morgan Healthcare Conference , Tuesday, January 8 , at 2:30 p.m. PT at the Westin St.

The press releases contained in this section of the website are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. bluebird bio disavows any obligation to update the information contained in such press releases after the date of their issuance.

Media Contacts

Jenn Snyder

VP, Corporate Communications

(617) 448-0281

JSnyder@bluebirdbio.com

 

Catherine Falcetti

Senior Director, Corporate Communications

(339) 499-9436

CFalcetti@bluebirdbio.com

 

Investor Contact

Elizabeth Pingpank

Director, Corporate Communications

(617) 914-8736

EPingpank@bluebirdbio.com